{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:26:34Z","timestamp":1783776394696,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Epidermolysis bullosa (EB) is a heterogeneous group of hereditary skin diseases caused by mutations in structural proteins at the dermal-epidermal junction. Dystrophic epidermolysis bullosa (DEB), one of its main types, is characterized by recurrent pruritic blisters, bullae, atrophy, and scarring, often accompanied by nail dystrophy. Dystrophic epidermolysis bullosa pruriginosa, also known as epidermolysis bullosa pruriginosa (EBP), is a rare clinical subtype of DEB. In addition to the common manifestations of skin blisters and ulcers, patients with EBP also present severe pruritus. Traditional treatments for EBP have limited efficacy. In this study, we report the case of a 59-year-old male patient with EBP who showed significant improvement in skin lesions and pruritus after 10\u202fmonths of treatment with tofacitinib, a pan-JAK inhibitor. This case highlights the potential of JAK inhibitors in treating EBP, although long-term safety requires further investigation.<\/jats:p>","DOI":"10.3389\/fmed.2025.1648732","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:12Z","timestamp":1761888252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Effective treatment of dystrophic epidermolysis bullosa pruriginosa with tofacitinib"],"prefix":"10.3389","volume":"12","author":[{"given":"Fang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2391452","DOI":"10.1080\/09546634.2024.2391452","article-title":"Emerging DNA & RNA editing strategies for the treatment of epidermolysis bullosa","volume":"35","author":"Koller","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s13555-024-01227-8","article-title":"Treatment of epidermolysis bullosa and future directions: a review","volume":"14","author":"Danescu","year":"2024","journal-title":"Dermatol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaad.2025.05.1449","article-title":"Dominant dystrophic epidermolysis bullosa across three distinct skin types","volume":"93","author":"Kaznoski","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1534734615572469","article-title":"Epidermolysis bullosa pruriginosa: case series and review of the literature","volume":"14","author":"Kim","year":"2015","journal-title":"Int J Low Extrem Wounds"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/bjd\/ljaf056","article-title":"Decoding COL7A1: a genetic roadmap to prognostication and personalized medicine in recessive dystrophic epidermolysis bullosa","volume":"192","author":"Lwin","year":"2025","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/1346-8138.17753","article-title":"Efficacy and safety of dupilumab monotherapy in patients with dystrophic epidermolysis bullosa: a retrospective study of 8 cases","volume":"52","author":"Dou","year":"2025","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"adv43588","DOI":"10.2340\/actadv.v105.43588","article-title":"Real-world experience with JAK inhibitors and dupilumab in dystrophic epidermolysis bullosa: a case report and literature review","volume":"105","author":"Ling","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1684\/ejd.2011.1583","article-title":"Novel and recurrent COL7A1 mutation in a Polish population","volume":"22","author":"Wertheim-Tysarowska","year":"2012","journal-title":"Eur J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00439-020-02199-3","article-title":"The human gene mutation database HGMD\u00ae: optimizing its use in a clinical diagnostic or research setting","volume":"139","author":"Stenson","year":"2020","journal-title":"Hum Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.3390\/ijms26094281","article-title":"Paw skin as a translational model for investigating fibrotic and inflammatory wound healing defects in recessive dystrophic epidermolysis bullosa","volume":"26","author":"De Gregorio","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e15146","DOI":"10.1111\/exd.15146","article-title":"Unveiling the value of C-reactive protein as a severity biomarker and the IL4\/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: a multiparametric cross-sectional study","volume":"33","author":"Quintana-Castanedo","year":"2024","journal-title":"Exp Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/bjd\/ljae182","article-title":"Dystrophic epidermolysis bullosa: from disease biology to biologic therapy","volume":"191","author":"Samuelov","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/exd.14481","article-title":"Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing","volume":"31","author":"Onoufriadis","year":"2022","journal-title":"Exp Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1002\/ski2.445","article-title":"Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa","volume":"4","author":"Hou","year":"2024","journal-title":"Skin Health Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/ced\/llaf053","article-title":"Refractory eosinophilic pustular folliculitis treated with tofacitinib: a case series and literature review","volume":"50","author":"Wang","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/1346-8138.16945","article-title":"Novel compound heterozygous mutations of the COL7A1 gene in a Chinese patient with recessive dystrophic epidermolysis bullosa pruriginosa and digestive symptoms successfully treated with tofacitinib","volume":"51","author":"Zhou","year":"2024","journal-title":"J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/ced.14998","article-title":"Successful use of tofacitinib in epidermolysis bullosa pruriginosa","volume":"47","author":"Chen","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1097\/MJT.0000000000001878","article-title":"Abrocitinib successfully treated dupilumab-resistant patients with rare dominant dystrophic epidermolysis bullosa with atopic dermatitis","volume":"32","author":"Hui","year":"2025","journal-title":"Am J Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e38854","DOI":"10.1097\/MD.0000000000038854","article-title":"Epidermolysis bullosa pruriginosa treated with baricitinib: a case report","volume":"103","author":"He","year":"2024","journal-title":"Medicine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/1346-8138.17079","article-title":"Efficacy of oral JAK1 or JAK1\/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: a retrospective case series","volume":"51","author":"Kwon","year":"2024","journal-title":"J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1001\/jamadermatol.2021.3174","article-title":"Epidermolysis bullosa pruriginosa treated with baricitinib","volume":"157","author":"Jiang","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15963","article-title":"Successful use of upadacitinib in treating a child with epidermolysis bullosa pruriginosa: a case report and literature review","author":"Wu","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/CCID.S499144","article-title":"A novel COL7A1 mutation in a patient with dystrophic epidermolysis bullosa. Successful treatment with upadacitinib","volume":"18","author":"Lai","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2024.2787","article-title":"Epidermolysis bullosa pruriginosa treated with upadacitinib","volume":"160","author":"Zhang","year":"2024","journal-title":"JAMA Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/1346-8138.17239","article-title":"A case of epidermolysis bullosa pruriginosa with a COL7A1 gene mutation successfully treated with upadacitinib","volume":"52","author":"Guo","year":"2025","journal-title":"J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1111\/jdv.18487","article-title":"Epidermolysis bullosa pruriginosa with extensive truncal involvement treated with upadacitinib","volume":"37","author":"Kim","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1648732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:23Z","timestamp":1761888263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1648732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":27,"alternative-id":["10.3389\/fmed.2025.1648732"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1648732","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1648732"}}